Hyperion Asset Management Ltd Acquires 61,669 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Hyperion Asset Management Ltd increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 55.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 172,514 shares of the medical equipment provider's stock after buying an additional 61,669 shares during the quarter. Intuitive Surgical accounts for approximately 3.0% of Hyperion Asset Management Ltd's holdings, making the stock its 12th largest holding. Hyperion Asset Management Ltd's holdings in Intuitive Surgical were worth $90,045,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Bennett Selby Investments LP boosted its stake in shares of Intuitive Surgical by 3.9% during the 4th quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider's stock worth $234,000 after acquiring an additional 17 shares during the last quarter. Onefund LLC grew its holdings in Intuitive Surgical by 1.9% during the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock valued at $494,000 after purchasing an additional 18 shares during the last quarter. LVW Advisors LLC grew its stake in Intuitive Surgical by 1.3% in the 4th quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider's stock worth $756,000 after acquiring an additional 19 shares in the last quarter. Wesbanco Bank Inc. lifted its position in shares of Intuitive Surgical by 1.6% in the 4th quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider's stock worth $635,000 after purchasing an additional 19 shares during the period. Finally, Journey Strategic Wealth LLC lifted its position in shares of Intuitive Surgical by 1.9% in the 4th quarter. Journey Strategic Wealth LLC now owns 1,039 shares of the medical equipment provider's stock worth $542,000 after purchasing an additional 19 shares during the period. Institutional investors and hedge funds own 83.64% of the company's stock.

Insiders Place Their Bets

In other news, EVP Brian Edward Miller sold 8,900 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the sale, the executive vice president now directly owns 5,758 shares of the company's stock, valued at $2,793,033.06. This represents a 60.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jami K. Nachtsheim sold 2,400 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the sale, the director now directly owns 6,371 shares of the company's stock, valued at $3,312,920. This represents a 27.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,680 shares of company stock valued at $16,854,345 in the last 90 days. Corporate insiders own 0.70% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Truist Financial cut their price objective on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Raymond James lifted their price target on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an "outperform" rating in a research report on Friday, January 24th. UBS Group lifted their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. BTIG Research set a $560.00 price objective on shares of Intuitive Surgical and gave the stock a "buy" rating in a research report on Monday, April 14th. Finally, Robert W. Baird dropped their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $598.95.

Intuitive Surgical Stock Performance

Intuitive Surgical stock traded up $1.99 during midday trading on Wednesday, reaching $565.94. The stock had a trading volume of 1,409,652 shares, compared to its average volume of 1,637,122. The firm's fifty day simple moving average is $501.31 and its 200-day simple moving average is $535.58. Intuitive Surgical, Inc. has a 1-year low of $386.00 and a 1-year high of $616.00. The stock has a market capitalization of $202.84 billion, a P/E ratio of 88.29, a price-to-earnings-growth ratio of 5.85 and a beta of 1.70.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. During the same period in the previous year, the company posted $1.50 EPS. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.